Lacosamide Solution
Product Images NDC 60687-847

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 60687-847). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100 mg/10 mL Lacosamide Oral Solution Cup Lid (100 mg 10 mL Lacosamide Oral Solution Cup Lid)

This is a prescription medication for Lacosamide oral solution, USP with a concentration of 100 mg/10 mL. The solution includes Phenylalanine 0.14 mg and is suitable for individuals with phenylketonuria. The text also contains product identification codes such as NDC60687-847-02 and indicates that it delivers 10 mL.*

FDA Label Image

200 mg/20 mL Lacosamide Oral Solution Cup Lid (200 mg 20 mL Lacosamide Oral Solution Cup Lid)

FDA Label Image

50 mg/5 mL Lacosamide Oral Solution Cup Lid (50 mg 5 mL Lacosamide Oral Solution Cup Lid)

This label provides information on Lacosamide A in oral solution form with a concentration of 50 mg per 5 mL. The solution contains Phenylalanine at a concentration of 0.07 mg. It is important not to freeze the solution. For full prescribing information and storage instructions, refer to the package insert. This product is intended for institutional use only and is distributed by American Health Packaging.*

FDA Label Image

Lacosamide Oral Solution Usp, 10 mg/ml Label (Label)

This is a description for Lacosamide (V) Oral Solution, USP. It is a prescription drug intended for institutional use only. The solution contains 10 mg of lacosamide USP per mL. It is important to dispense it with the accompanying Medication Guide to each patient. This solution should be stored at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). It should not be frozen.*

FDA Label Image

Figure 1 (Median Percent Reduction in Seizure Frequency per 28 days from Baseline to the Maintenance Phase by Dose)

The text provides a figure showing the Median Percent Reduction in Seizure Frequency per 28 days from Baseline to the Maintenance Phase for different doses in Studies 2, 3, and 4. It includes data comparing the reduction in seizure frequency with Lacosamide and Placebo at varying dose levels. Study results and statistically significant differences are mentioned.*

FDA Label Image

Figure 2 (Proportion of patients by Responder Rate for Lacosamide and Placebo Groups in Studies 2, 3, and 4)

FDA Label Image

Figure 3 (Kalpan-Meier Analysis of Time to 2nd PGTC Seizure (Study 5) Analysis Set: Modified Full Analysis Set)

This text describes a Kalpan-Meier Analysis of Time to 2" PGTC Seizure for Study 5, with the analysis set as the Modified Full Analysis Set. The figure illustrates data on patients still at risk in the study at different time points. The numbers at the bottom of the figure represent the patients continuing in the study without an event or censoring before the specified timepoint.*

FDA Label Image

Structural Formula (Lacosamide Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.